This Article Full Text Full Text (PDF) All Versions of this Article: 54/5/951    most recent HYPERTENSIONAHA.109.135061v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Kaplan, N. M. PubMed PubMed Citation Articles by Kaplan, N. M. Related Collections Cardiovascular Pharmacology Primary prevention Clinical Studies Other Treatment

(Hypertension. 2009;54:951.)
© 2009 American Heart Association, Inc.

Editorial

The Choice of Thiazide Diuretics

Why Chlorthalidone May Replace Hydrochlorothiazide

From the Hypertension Division, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Tex.

Correspondence to Norman M. Kaplan, 5323 Harry Hines Blvd, Dallas, TX 75390-8586. E-mail Norman.kaplan@utsouthwestern.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Thiazide diuretics were introduced in the United States for the treatment of hypertension in 1957. The first of these, chlorothiazide, was soon accompanied by a large number of other sulfonamide derivatives, including chlorthalidone. Hydrochlorothiazide (HCTZ) rapidly became the most commonly prescribed antihypertensive drug in the United States, whereas bendroflumethiazide was most popular in the United Kingdom. The initial popularity of HCTZ in the United States was abetted by its use in the first controlled trial of the treatment of nonmalignant hypertension, the Veterans’ Affairs Cooperative Study.¹ The starting dose of HCTZ was 50 mg/d, and it was used along with reserpine and hydralazine. A number of other trials published in the 1970s all used higher doses of diuretic, for example, 50 mg of HCTZ per day.²

For reasons unknown to me, chlorthalidone was chosen to be the diuretic in the first large controlled trial of the treatment of hypertension, the Hypertension Detection and Follow-Up Program.³ In the Hypertension Detection and Follow-Up Program, all 10 940 patients were started on chlorthalidone from 25 to 100 mg/d. Other drugs were added to achieve control of the blood pressure. In addition, half were assigned to "referred" care and the other half to more closely monitored and intensively treated "stepped" care. The stepped care–treated half achieved a 4.4% further reduction in diastolic blood pressure and a 17.0% reduction in mortality.

In other large, placebo controlled trials published in the early 1980s, other diuretics were used: chlorothiazide in the Australian trial,⁴ HCTZ in the Oslo . . . [Full Text of this Article]